TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04706455

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: sodium hyaluronate 0.1%
Description: Instillation of one drop sodium hyaluronate 0.1%
Study: NCT01405586

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000mg/m2 days 1 and 8 every 3 weeks for 6 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: 1200 mg/m2 days 1 and 8 every 3 weeks for 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 60 mg/m2 day 1 every 3 weeks for 6 cycles
Study: NCT01506141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idursulfase-IT
Description: Participants will receive Idursulfase-IT once monthly at the dose used in study HGT-HIT-045 via intrathecal drug delivery device (IDDD).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elaprase
Description: Participants will receive weekly IV infusions of commercially available Elaprase.
Study: NCT00565474

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluvastatin
Description: Graft vasculopathy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluvastatin
Description: Graft vasculopathy
Study: NCT04706455

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: sodium hyaluronate 0.3%
Description: Instillation of one drop sodium hyaluronate 0.3%
Study: NCT01655485

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient teaching
Description: The Social script application is an story book on the iPAD with photos and script explaining the steps of getting a medical image such as a CAT scan from the perspective of the child.
Study: NCT04708561

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Speech and language therapy
Description: The intervention focuses on understanding the thoughts of the characters. Twenty written stories will be used, which end with statements that can be interpreted literally, ironically, as a lie, a request or a faux-pas (maladroitness). At the end of each story, the participant should explain what the characters want to mean by their statement.~To help the participant in his understanding of the character's intention, he will be asked:~1) To mention as many intentions as possible that can be associated with the target statement presented out of context (eg: it's hot here that can be interpreted literally, ironically, as a lie or a request) and to imagine contexts in connection with interpretation; 2. Analyze the relevant elements of the context (environment, the relationship between the characters, knowledge of the characters); 3. To judge the probability of the possible interpretations (pt 1) by justifying using the elements of the context analyzed previously (pt 2).
Study: NCT03829644

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Horizon 627 Lumbar Brace, Aspen Medical Company, Oak Canyon, Irvine, CA 92618
Description: The brace is an FDA Class I device, one-size adjustable design to fit waists ranging from 24-70 inches. Participants will be instructed to wear the brace for six weeks. As this brace is semi-rigid, it does not prevent motion - only reduces motion in the lumbar areas. Our prior work and that of others have shown that this type of bracing does not reduce spinal function and is not associated with atrophy.
Study: NCT01649778

Intervention type: DRUG
Intervention: Pazopanib
Description: Prospective Observational study collecting real world data on Pazopanib in patients with advanced or metastatic Renal Cell Carcinoma. Study is considered non-interventional, no drug will be provided. No study visits or procedures are mandated per protocol.
Study: NCT04187781

Intervention type: DEVICE
Group type: OTHER
Intervention: external microphone
Description: External microphone is developed for direct transmission of speech into the hearing aids for better speech intelligibility, especially in noise.

Intervention type: DEVICE
Group type: OTHER
Intervention: external microphone
Description: External microphone is developed for direct transmission of speech into the hearing aids for better speech intelligibility, especially in noise.
Study: NCT04263155

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Body Project
Description: The Body Project is a 4-hour dissonance-based program designed to address body image concerns and prevent eating disorders. The curriculum consists of written, verbal, and behavioral exercises that provide participants with the opportunity to voluntarily and publicly critique the appearance ideal.
Study: NCT00095888

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: triapine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT00120302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimecrolimus
Description: Pimecrolimus cream 1 %

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching vehicle cream
Study: NCT02317471

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous gp96 vaccination
Description: Vaccination of gp96 derived from autologous tumor tissue. Treatment will be started between 3-6 weeks after the surgery.~gp96 of 25ug in 1mL normal saline s.c. on days 1 of each cycle, up to a maximum of 10 doses (1 cycle= 7 days). 200-400mg cyclophosphamide i.v. 1-3 days before each gp96 infusion.

Intervention type: DRUG
Group type: OTHER
Intervention: Oxaliplatin+S-1
Description: Treatment will be start at the 5th week after the surgery.~S-1: 40\~60mg bid，d1\~14 q3W; oxaliplatin:130mg/m2，iv drip for 2h，d1,q3W 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin+S-1
Description: Treatment will be start at the 5th week after the surgery.~S-1: 40\~60mg bid，d1\~14 q3W; oxaliplatin:130mg/m2，iv drip for 2h，d1,q3W 6 cycles.
Study: NCT01281514

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated liposomal doxorubicin hydrochloride
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03758053

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT03141138

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TDENV-PIV
Description: Dosage: 0.5 mL of DENV serotypes 1-4 (4 µg / serotype) in alum adjuvant Mode of administration: intramuscular (IM) into the subject's upper arm, deltoid area of the subject's arm; vaccination will be given in the non-dominant arm whenever possible

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TDENV-PIV
Description: Dosage: 0.5 mL of DENV serotypes 1-4 (4 µg / serotype) in alum adjuvant Mode of administration: intramuscular (IM) into the subject's upper arm, deltoid area of the subject's arm; vaccination will be given in the non-dominant arm whenever possible

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TDENV-LAV F17
Description: Dosage: 0.5 mL of the post-transfection LAV F17 vaccine Mode of administration: subcutaneously into the upper-outer triceps/deltoid area of the subject's arm; vaccination will be given in the non-dominant arm whenever possible.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TDENV-LAV F17
Description: Dosage: 0.5 mL of the post-transfection LAV F17 vaccine Mode of administration: subcutaneously into the upper-outer triceps/deltoid area of the subject's arm; vaccination will be given in the non-dominant arm whenever possible.
Study: NCT03212742

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: We propose 7 dose levels to reach the target dose of 400 mg per day (200 mg twice daily) of olaparib continuously DL1 (starting dose level) : Olaparib 50 mg Q12H Monday to wednesday DL2 : Olaparib 100mg Q12H Monday to wednesday DL3: Olaparib 100mg Q12H Monday to friday DL4 : Olaparib 200mg Q12H Monday to wednesday DL5: Olaparib 200mg Q12H Monday to friday DL6: Olaparib 200mg Q12H, continously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide (TMZ)
Description: TMZ will be given at the dose of 75mg/m²/day during radiotherapy period. TMZ will be re-introduced 4 weeks after the end of radiotherapy at the dose of 150mg/m²/day on days 1 to 5 every 28 days, for a total of 6 cycles.
Study: NCT04693494

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training program
Description: Training program consisting in 4 sessions with information about milestones to achieve and advices for motor development. Triptychs and short videos containing the main points containing the main points.
Study: NCT02283554

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: open flap debridement (OFD)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: open flap debridement (OFD)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: open flap debridement (OFD)
Study: NCT03212742

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT (Intensity Modulated Radiation Therapy)
Description: Radiotherapy consists of fractionated focal irradiation at a dose of 2 Gy per fraction given once daily five days per week over 6 weeks, for a total dose of 60 Gy by 3D- Intensity-Modulated RT (IMRT)
Study: NCT02170571

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate
Study: NCT01314586

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: secoisolariciresinol diglucoside-containing extract of flaxseed
Description: 0, 150 or 300 mg/day as 2 pills taken at breakfast and dinner, dietary counseling to comply with NCEP Step I diet

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: secoisolariciresinol diglucoside-containing extract of flaxseed
Description: 0, 150 or 300 mg/day as 2 pills taken at breakfast and dinner, dietary counseling to comply with NCEP Step I diet

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: secoisolariciresinol diglucoside-containing extract of flaxseed
Description: 0, 150 or 300 mg/day as 2 pills taken at breakfast and dinner, dietary counseling to comply with NCEP Step I diet
Study: NCT00832299

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX
Description: 6 cycles of neo-adjuvant mFOLFOX6

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: total mesorectal excision (TME)
Description: TME will be done 4-6 weeks after 6 cycles of neo-adjuvant FOLFOX.
Study: NCT03144154

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-hypnosis + Self-care
Description: Our groupal intervention is divided into 8 weekly 2-hour sessions in which one self-hypnosis exercise is proposed to participants. Self-care techniques are also discussed (knowing our own needs, self-respect, assertiveness, coping with ruminations...) and homework assignments are proposed to participants, in order to foster positive change.
Study: NCT04744246

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: load carriage
Description: 35 pound load carried on the back

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: load carriage
Description: 35 pound load carried on the back
Study: NCT02659254

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sirolimus Target Eluting Bioresorbable Vascular Scaffold
Description: Implantation of the Sirolimus Target Eluting Bioresorbable Vascular Scaffold
Study: NCT01658436

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEZ235 (Stage 1)
Description: The investigational study drug used in this trial was BEZ235, which was supplied as 50mg, 200mg, 300mg, and 400mg solid dispersion sachets. Supply as 200mg and 50mg were provided for dose reduction. Patients were instructed to take the contents of one sachet of BEZ235 twice a day in the morning within 30 minutes after a light meal (breakfast).
Study: NCT04311021

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT03771924

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: inorganic phosphate
Description: Sodium phosphate

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Sodium chlorid
Study: NCT02283554

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: open flap debridement (OFD)
Study: NCT00610298

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: whole body vibration using a Galileo vibrating platform
Description: whole body vibration at 20 hertz for 3 minutes 3 to 5 days per week for up to 12 weeks
Study: NCT01094847

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWJ1252
Description: tablet(oral) administration following the schedule of each arm

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DWJ1252
Description: tablet(oral) administration following the schedule of each arm
Study: NCT00013533

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem cell transplantation
Description: \>3 x 106/kg CD34+ stem cells by IV infusion
Study: NCT03761992

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Gingko Baloba
Description: Tablets

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets
Study: NCT03239392

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BNZ132-1-40
Description: Injectable PEGylated peptide antagonist that binds to the common gamma chain (γc) signaling receptor for the cytokines interleukin (IL)-2, IL-9, and IL-15
Study: NCT00035243

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epothilone b
Description: EPO906 administered intravenously at 2.5 mg/m2 as a 5 minute bolus infusion repeated every week for three weeks followed by one week off The final tables and data is not in yet, so I cannot give you info on safety issues.
Study: NCT03790202

Intervention type: DEVICE
Intervention: VistaCare®
Description: Controlled atmosphere wound healing device
Study: NCT02283554

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Platelet rich fibrin (PRF)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Platelet rich fibrin (PRF)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Study: NCT03280667

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus denosumab
Description: Pembrolizumab 200 mg IV every 3 weeks plus denosumab 120 mg SC on day 1, 8, 22 and then every 3 weeks with daily oral calcium and vitamin D
Study: NCT03272425

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lesinurad/allopurinol 200/300 FDC tablets
Description: Test Drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lesinurad/allopurinol 200/300 FDC tablets
Description: Test Drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lesinurad/allopurinol 200/300 FDC tablets
Description: Test Drug
Study: NCT00655902

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Trans fat (soy bean oil)
Description: Industrially produced trans fatty acid from soy bean oil (15 g/d for 16 weeks). The fat (a total of 25 g/d) will be baked into buns.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control fat (sunflower oil)
Description: Control fat from sunflower oil, with 60% oleic acid (in total 25 g/d for 16 weeks). The fat will be baked into buns.
Study: NCT00107341

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Study: NCT00789425

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (starch). A supplement with 1000 mg calcium per day will be supplied together with the active treatment.
Study: NCT03272425

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lesinurad/allopurinol 200/300 FDC tablets
Description: Test Drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lesinurad 200 mg
Description: Comparator 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lesinurad 200 mg
Description: Comparator 1
Study: NCT02904278

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Teen Pocket PATH® Mobile Application
Description: Participants in the intervention group will receive the mobile application for improving adherence to their post-transplant medications. The intervention will prompt, remind, and warn participants when medications are due, inform parents when medication management is completed, and engage parents when no action is undertaken.

Intervention type: OTHER
Group type: OTHER
Intervention: Control Group: Standard of Care
Description: Adolescents and parents/guardians assigned to the Standard Care Condition will receive standard clinical care per standard site procedures.
Study: NCT03272425

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lesinurad 200 mg
Description: Comparator 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lesinurad 200 mg
Description: Comparator 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: allopurinol 300 mg
Description: Comparator 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: allopurinol 300 mg
Description: Comparator 2
Study: NCT04418648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Toripalimab consolidation (240 mg) via iv infusion once every 3 weeks. Administration of toripalimab will commence on Day 1 following randomisation to toripalimab after confirmation of eligibility and will continue on a Q3W schedule for a maximum duration of 6 months.
Study: NCT05395975

Intervention type: DEVICE
Intervention: Oxygen Reserve Index
Description: It is a new non-invasive and continuous measurement parameter that aims to provide information about the oxygen status of patients in the moderately hyperoxic range (100 mmHg\< PaO2 ≤ 200 mmHg).

Intervention type: DEVICE
Intervention: Oxygen Reserve Index
Description: It is a new non-invasive and continuous measurement parameter that aims to provide information about the oxygen status of patients in the moderately hyperoxic range (100 mmHg\< PaO2 ≤ 200 mmHg).
Study: NCT00567814

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metyrapone
Description: Twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metyrapone
Description: Twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxazepam
Description: Twice Daily
Study: NCT03272425

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: allopurinol 300 mg
Description: Comparator 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: allopurinol 300 mg
Description: Comparator 2
Study: NCT01224795

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peramivir
Description: Adults (≥ 18 years): Peramivir 600 mg, administered intravenously. Adolescents (12 to \< 18 years): Peramivir 10 mg/kg (not to exceed a maximum dose of 600 mg), administered intravenously.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Placebo Peramivir, administered intravenously.
Study: NCT02456077

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multimodal Vaccine Program
Description: Efforts will be made to collaborate with pediatric and family medicine offices to utilize a multimodal intervention to improve adolescents' HPV immunization rates. As part of the overall intervention, four intervention strategies will be used: 1) a tailored website, iVac -HPV , 2) Motivational Interview Training for providers, 3) HPV Fact Sheets and 4) The Decision Aid for HPV Vaccines
Study: NCT02647294

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Maxicor
Description: Patients with NAFLD will be randomly allocated to receive or n-3 PUFA (3,6 g/day, oral treatment) or placebo (1:1).
Study: NCT00567814

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxazepam
Description: Twice Daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Twice daily
Study: NCT03678493

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplant (FMT)
Description: Oral Capsule

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplant (FMT)
Description: Oral Capsule

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral Capsule

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral Capsule
Study: NCT02647294

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients with NAFLD will be randomly allocated to receive or placebo or n-3 PUFA for 12 months (1:1).
Study: NCT03999320

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sophrology sessions
Description: 8 sophrology sessions, approximately 60 minutes each, spread over 12 months

Intervention type: OTHER
Group type: OTHER
Intervention: usual care
Description: usual care